Immunological predictors of different responses to combination therapy with interferon α and ribavirin in patients with chronic hepatitis C

Journal of Gastroenterology

Volumn 38, Issue 3, 2003, Pages 254-259

  Amaraa, Ravdan ^a   Mareckova, Helena ^a   Urbanek, Petr ^a   Fucikova, Terezie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Chronic hepatitis C; Cytotoxic T lymphocytes; Interferon ; Ribavirin; T helper lymphocytes

Indexed keywords

ALPHA INTERFERON; CD28 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 2; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HELPER CELL; HEPATITIS C; HUMAN; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TH1 CELL; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; RIBAVIRIN;

EID: 0037847610     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350300044     Document Type: Article

References (15)

1. National Institute of Health Consensus Development Conference. Management of hepatitis C. Hepatology 1997;Suppl 1:2S-10S.
2. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviours of acute hepatitis C virus infection are associated with different vigour of the anti-viral cell mediated immune response. J Clin Invest 1996;98:706-14.
3. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-82.
4. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
5. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
6. Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993;74:2385-90.
7. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-4.
8. Bergamini A, Bolacchi F, Cepparulo M, Demin F, Uccella I, Bongiovanni B, et al. Treatment with ribavirin and interferon-α reduces interferon-γ expression in patients with chronic hepatitis C. Clin Exp Immunol 2001;123:459-64.
9. Fang S-H, Lai M-Y, Hwang L-H, Yang P-M, Chen P-J, Chiang B-L, et al. Ribavirin enhances interferon-γ levels in patients with chronic hepatitis C treated with interferon-α. J Biomed Sci 2001;8:484-91.
10. Kawamura C, Nakajima S, Kuroki T, Monna T. Two-dimensional analysis of production of IL6 and TNFα can predict the efficacy of IFN-α therapy. Hepatogastroenterology 1999;46:2941-5.
11. Fabris C, Soardo G, Falleti E, Toniutto P, Vitulli D, Federico E, et al. Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-α in chronic hepatitis C. J Interferon Cytokine Res 1998;18:705-9.
12. Neuman MG, Benhamou J-P, Martinot M, Boyer N, Shear NH, Malkiewicz I, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin Biochem 1999; 32:537-45.
13. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
14. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999;162:6681-9.
15. Perrela A, Conca P, Tarantino G. CD8+/CD38+: immune activity and clinical significance in HCV patients with and without interferon therapy. Eur Rev Pharmacol Sci 2000;4:127-31.